MedTrace Logo

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-03-25

No results posted yet for this study

Summary

This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.

Conditions

  • Scarring Alopecia
  • Frontal Fibrosing Alopecia
  • Lichen Planopilaris
  • Central Centrifugal Cicatricial Alopecia
  • Central Centrifugal Scarring Alopecia

Interventions

DRUG

Topical gabapentin

topical gabapentin 6% solution

Sponsors & Collaborators

Principal Investigators

  • Maria K Hordinsky, MD · University of Minnesota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-28
Primary Completion
2021-10-11
Completion
2021-10-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346668 on ClinicalTrials.gov